TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Saniona AB ( (SE:SANION) ).
Saniona AB reported significant financial growth in Q3 2025, highlighted by a lucrative licensing agreement with Jazz Pharmaceuticals for SAN2355, aimed at treating epilepsy. This partnership, alongside the selection of SAN2668 for severe pediatric epilepsy syndromes, underscores Saniona’s strategic positioning to leverage global demand for innovative CNS treatments, potentially unlocking substantial long-term value for shareholders.
The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK18.50 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona AB operates in the biotechnology industry, focusing on developing first-in-class therapies for central nervous system (CNS) disorders. The company is committed to advancing its internal pipeline and has a market focus on neurological and psychiatric treatments.
Average Trading Volume: 1,059,024
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.18B
See more data about SANION stock on TipRanks’ Stock Analysis page.